Research programme: type 2 diabetes therapeutics - Southeast TechInventures

Drug Profile

Research programme: type 2 diabetes therapeutics - Southeast TechInventures

Latest Information Update: 11 Aug 2016

Price : $50

At a glance

  • Originator Southeast TechInventures
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Metabolic syndrome; Type 2 diabetes mellitus

Highest Development Phases

  • Research Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 11 Aug 2016 Research programme: type 2 diabetes therapeutics - Southeast TechInventures is available for licensing as of 11 Aug 2016. http://www.setechinv.com/index.php
  • 10 Aug 2016 Early research in Metabolic syndrome in USA (unspecified route)
  • 10 Aug 2016 Early research in Type-2 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top